Professional Documents
Culture Documents
Biofar
Biofar
Elimination
100 mg Excretion In the mass balance study, 84% of the dose was
received in the feces and 12% of the dose was
recovered in the urine, with less than 1% of the
dose excreted as unchanged acalabrutinib in urine
background
reducing agents (ARAs) such as the elevated gastric pH
proton pump inhibitors (PPIs),
the PPI omeprazole for 5
levels that occur when
where concomitant use results days decreased
ARAs are administered,
in reduced area under the AUC by 43% in healthy
referred to here as the
plasma drug concentration–time subjects (Deisseroth,
“ARA effect”
curve (AUC) values (Patel et al., 2019)
2020
Physical
Physical and Chemical Stability Methods
chemical
Tablet In Vitro Dissolution
Performance